Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-25-027457
Filing Date
2025-07-28
Accepted
2025-07-28 07:01:18
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ny20050586x3_defa14a.htm DEFA14A 10354
2 ny20050586x3_nc01.jpg GRAPHIC 3183195
3 ny20050586x3_nc02.jpg GRAPHIC 3979663
  Complete submission text file 0001140361-25-027457.txt   9860494
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-322-1602
Grace Therapeutics, Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 0331
Type: DEFA14A | Act: 34 | File No.: 001-35776 | Film No.: 251152914
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)